Nivolumab has been approved by the FDA for use as an adjuvant treatment for urothelial carcinoma

Share This Post

August 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence following radical resection.

This is the first time the FDA has approved an adjuvant treatment for high-risk UC patients. The findings also backed up the decision to convert nivolumab’s accelerated authorisation for advanced/metastatic UC to a standard approval.

Nivolumab was studied in CHECKMATE-274 (NCT02632409), a randomised, double-blind, placebo-controlled trial in patients with UC of the bladder or upper urinary tract (renal pelvis or ureter) who were at high risk of recurrence within 120 days of radical resection. Patients were randomly assigned (1:1) to receive nivolumab 240 mg or placebo by intravenous infusion every two weeks until recurrence or intolerable toxicity, with a maximum treatment period of one year.

In the intent-to-treat (ITT) group and in patients with tumours expressing PD-L1 less than 1%, the primary effectiveness objective was investigator-assessed disease-free survival (DFS). Time to first recurrence (local urothelial tract, local non-urothelial tract, or distant metastatic) or death was used to determine DFS. For all primary objectives, a statistically significant improvement in DFS was reported in participants on the nivolumab arm vs. placebo at a prespecified interim analysis. In the ITT analysis, patients who got nivolumab had a median DFS of 20.8 months (95 percent CI: 16.5, 27.6) compared to 10.8 months (95 percent CI: 8.3, 13.9) in patients who received placebo (HR 0.70; 95 percent CI: 0.57, 0.86; p=0.0008). Patients who received nivolumab had a median DFS of not achieved (95 percent confidence interval: 21.2, not estimable) compared to 8.4 months (95 percent confidence interval: 5.6, 21.2) for those who got placebo (HR 0.55; 95 percent confidence interval: 0.39, 0.77; p=0.0005).

The unstratified DFS hazard ratio estimate was 0.83 in an exploratory examination of patients with PD-L1-negative tumours (58 percent) (95 percent CI: 0.64, 1.08). With 33 percent of deaths in the entire randomised population, OS data is still in its infancy. There were 37 deaths in the UTUC subpopulation (20 in the nivolumab arm, 17 in the placebo arm).

Rashes, weariness, diarrhoea, pruritus, musculoskeletal pain, and urinary tract infection were the most prevalent adverse effects observed in approximately 20% of participants who received nivolumab in CHECKMATE-274.

Nivolumab is prescribed at a dose of 240 mg every two weeks or 480 mg every four weeks for the adjuvant treatment of UC.

 

Reference: https://www.fda.gov/

Check details here.

Take second opinion on urothelial carcinoma treatment


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

After amazing growth of CAR T-Cell therapy what's next
CAR T-Cell therapy

After amazing growth of CAR T-Cell therapy: what’s next?

CAR T-cell therapy has rapidly transformed cancer treatment by reprogramming a patient’s T-cells to attack cancer cells, demonstrating remarkable success in hematologic cancers. Advances in genetic engineering, regulatory support, and investment are driving further expansion. Researchers are now tackling the challenges of applying this therapy to solid tumors, aiming to enhance efficacy and accessibility, marking a new era in personalized cancer therapy and immunotherapy.

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS
Cancer

Lutetium Lu 177 dotatate is approved by USFDA for pediatric patients 12 years and older with GEP-NETS

Lutetium Lu 177 dotatate, a groundbreaking treatment, has recently received approval from the US Food and Drug Administration (FDA) for pediatric patients, marking a significant milestone in pediatric oncology. This approval represents a beacon of hope for children battling neuroendocrine tumors (NETs), a rare but challenging form of cancer that often proves resistant to conventional therapies.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy